Potential pharmacological mechanisms of tanshinone IIA in the treatment of human neuroblastoma based on network pharmacological and molecular docking Technology
Frontiers in Pharmacology · 11.03.2024 · 15
DOI: 10.3389/fphar.2024.1363415 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 11.03.2024. Verfasst von Ning Tang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrative Medicine, Liaoning University of Traditional Chinese Medicine Xinglin College, Shenyang, China. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Tanshinone IIA (Tan-IIA) is the main bioactive component of Chinese herbal medicine salvia miltiorrhiza (Danshen). Sodium sulfonate of Tan-IIA is widely used in the treatment of cardiovascular and cerebrovascular diseases. Tan-IIA also has inhibitory effects on tumor cells such as gastric cancer, but its therapeutic effect and mechanism on human neuroblastoma have not been evaluated, so its pharmacological mechanism is systematically evaluated by the combined method of network pharmacology and molecular docking. PharmMapper and SwissTargetPrediction predicted 331 potential Tan-IIA-related targets, and 1,152 potential neuroblastoma-related targets were obtained from GeneCards, DisGeNET, DrugBank, OMIM and Therapeutic Target databases (TTD), 107 common targets for Tan-IIA and neuroblastoma. Through gene ontology (GO) functional annotation, Kyoto Encyclopedia of Genes and Genomesa (KEGG) pathway enrichment, protein-protein interaction (PPI) network and cytoHubba plug-in, 10 related signal pathways (Pathways in cancer, PI3K-Akt signaling pathway, Prostate cancer, etc.) and 10 hub genes were identified. The results of molecular docking showed that Tan-IIA could interact with 10 targets: GRB2, SRC, EGFR, PTPN1, ESR1, IGF1, MAPK1, PIK3R1, AKT1 and IGF1R. This study analyzed the related pathways and targets of Tan-IIA in the treatment of human neuroblastoma, as well as the potential anticancer and anti-tumor targets and related signaling pathways of Tan-IIA, which provides a reference for us to find and explore effective drugs for the treatment of human neuroblastoma.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Integrative Medicine, Liaoning University of Traditional Chinese Medicine Xinglin College, Shenyang, China.
- Department of Integrative Medicine, Dalian Medical University, Dalian, China.
- Department of Acupuncture and Massage, Liaoning University of Traditional Chinese Medicine Xinglin College, Shenyang, China.
Zitieren
APA
Tang, N., Wang, Y., Miao, J., Zhao, Y., Cao, Y., Sun, W., Zhang, J., Sui, H., & Li, B. (2024). Potential pharmacological mechanisms of tanshinone IIA in the treatment of human neuroblastoma based on network pharmacological and molecular docking Technology. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1363415
Vancouver
Tang N, Wang Y, Miao J, Zhao Y, Cao Y, Sun W, et al. Potential pharmacological mechanisms of tanshinone IIA in the treatment of human neuroblastoma based on network pharmacological and molecular docking Technology. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1363415
BibTeX
@article{Tang2024,
author = {Tang, Ning and Wang, Yan and Miao, Jiarui and Zhao, Yang and Cao, Yue and Sun, Wentao and Zhang, Jingke and Sui, Hua and Li, Bing},
title = {Potential pharmacological mechanisms of tanshinone IIA in the treatment of human neuroblastoma based on network pharmacological and molecular docking Technology},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1363415}
}
EUVIMED